Ann: BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test, page-43

if any holders follow the use of AI (artificial intelligence) in pathology they will twig to the relevance of this announcement. there are a number of Aus companies who are quietly racking up FDA approval of AI modules for pathology in urine & blood samples. there presentations give data on the use and growth of automated pathology processing. the approvals of the modules in areas such as urine analysis - are to date a 100% positive in outperforming human analysis. there are a number of other indication where AI is used to outperform human analysis - the visible blotting on the sample is indicative that AI may be able to use the BD1 tech in histopathology of tissue samples. this is significant because - the human error rate is significant see